FEIBA

Also found in: Acronyms.

FEIBA

Factor VIII inhibitor–see there, or factor VIII bypassing activity. See Prothrombin complex concentrate.

Mentioned in ?

prothrombin complex concentrate

References in periodicals archive ?

In rats receiving rivaroxaban, high-dose 4F-PCC was shown to produce the most profound decrease in mesenteric bleeding time (versus FEIBA and activated factor VII).

Clinical Applications of 4-Factor Prothrombin Complex Concentrate: A Practical Pathologist's Perspective

Resultados similares se vieron en los estudios internacionales ProFEIBA y PROOF donde se utilizaron dosis mas altas de FEIBA (~85 IU/kg) con reducciones del 61% y 72.

Profilaxis en pacientes con hemofilia que tienen inhibidores de alta respuesta

The approval is based on data from a Phase III trial known as FEIBA PROOF, under which treatment with a FEIBA prophylactic regimen indicated a 72% reduction in median annual bleed rate against treatment with an on-demand regimen.

Baxter International receives approval for FEIBA

A retrospective postlicensure survey of FEIBA efficacy and safety.

Profilaxis con CCPa en pacientes con hemofilia A con inhibidores de alta respuesta: una estrategia alternativa al estandar de tratamiento

A baboon model of rivaroxaban-associated bleeding also showed potential utility of FEIBA and rFVIIa in rivaroxaban reversal.

Novel Oral Anticoagulants: Efficacy, Laboratory Measurement, and Approaches to Emergent Reversal

According to Baxter, FEIBA is the first and only FDA-approved treatment for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with haemophilia A or B who have developed inhibitors.

Baxter's FEIBA receives US FDA approval for FEIBA for prophylactic treatment of haemophilia patients with inhibitors

Baxter, a United States- based healthcare company, has submitted a biologics license application supplement to the United States Food and Drug Administration for the approval of its prophylaxis treatment of FEIBA NF [Anti-Inhibitor Coagulant Complex], Nanofiltered and Vapor Heated, it was reported yesterday.

Baxter submits biologics license application supplement for prophylaxis treatment of FEIBA NF

3, letter A) of HG395 / 2016): 1 Asparaginazum 10,000 IU 580 530 lei lei 2 Calcii folinas 3 Cytarabinum Dacarbazinum 950 lei 140 lei 4 5 6 Leuprorelinum Fluorouracilum 380 lei 580 lei lei 7 August 1420 Melphalanum 50 mg Methotrexatum 660 lei 9 COMPLEX ANTIINHIBITORI coagulation - FEIBA 1000 IU or equivalent 3620 lei way collateralisation of participation: the way up the guarantee of participation: - by letter of guarantee - in cash, by deposit at the cashier of the hospital - by RO40TREZ4365006XXX007323 account payment order, TREASURY BAIA MARE, fiscal code 3694594 - with a guarantee instr